Program Leadership

UAMS’ KL2 Program is led by W. Brooks Gentry, M.D., professor in the department of  Anesthesiology and the department of Pharmacology and Toxicology.

Dr. Gentry has been a clinical and translational scientist since 1992, when he did his fellowship training in clinical pharmacology and pharmacokinetics at Northwestern University’s Feinberg School of Medicine. He is Professor and former Chair of the UAMS Department of Anesthesiology. He has collaborated in the development of medications for substance abuse and has had NIH funding since 1996. He has mentored numerous medical and graduate students, and residents in research and clinical medicine. He is a founding member, manager and Chief Medical Officer of InterveXion Therapeutics, LLC, a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders.  The company’s lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the central nervous system. IXT-m200 is currently being tested in Phase 2 proof-of-concept study (STAMPOUT).  InterveXion is also developing a novel vaccine (IXT-v100) against methamphetamine and will apply for funding to support a Phase 1 study of the vaccine this year. The company is responsible for 7 patents related to IXT-m200 and IXT-v100.

Nia Indelicato
Nia Indelicato, MNO, CRS
Assistant Director of Programs- Pilots, KL2, & Profiles
Brooks Gentry
Brooks Gentry, M.D.
Director, KL2 Scholar Program
Miesha Hall
Miesha Hall, MHA, CHAA
KL2 Program Manager